查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1494853

2030 年勝胜肽治療市場預測：按類型、給藥途徑、製造商類型、分子類型、技術、應用、最終用戶和地區進行的全球分析

Peptide Therapeutics Market Forecasts to 2030 - Global Analysis By Type (Branded, Generic, Innovative and Other Types), Route of Administration, Manufacturer Type, Molecule Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2024 年全球勝胜肽治療市場規模為 491.5 億美元，預計預測期內年複合成長率為 7.63%，到 2030 年將達到 764.1 億美元。

胜肽療法是一類令人興奮的新型藥物，它利用胜肽（短鏈氨基酸）來靶向和改變特定的生理途徑。它們具有卓越的選擇性和作用於多種生物標的（包括荷爾蒙、酵素和受體）的能力，使得這些治療方法特別有用。當將新治療方法與舊的小分子藥物進行比較時，這種精確度可以開發出副作用較少的治療方法。此外，利用創新方法治療糖尿病、癌症和細菌感染等疾病，胜肽療法已應用於腫瘤學、內分泌學和感染疾病等醫學專業。

據美國糖尿病協會稱，胜肽療法是糖尿病治療的重要進步，與傳統治療方法相比，可以改善血糖控制並減少副作用。

慢性病增加

糖尿病、癌症、心臟病和神經系統疾病等慢性病在全球的盛行率不斷上升，推動了對更複雜治療方法的需求。胜肽療法由於能夠精確靶向患病細胞和途徑，因此為傳統療法提供了一個有前景的替代方案。例如，GLP-1受體促效劑是胜肽藥物，對糖尿病患者的血糖控制具有優異的效果。此外，胜肽治療市場受到慢性病患者數量不斷增加的推動，導致對更安全、更有效的治療的需求增加。

製造成本增加

勝胜肽治療藥物是使用昂貴且複雜的合成技術製造的，例如重組 DNA 技術和固相勝胜肽合成 (SPPS)。這些程序需要昂貴的機械、高度純化的試劑和嚴格的品管程序，以確保所需產品的純度和效力。此外，從實驗室生產擴大到商業規模可能會令人望而卻步。由於製造成本高昂，這些產品最終價格昂貴，這可能會限制可負擔性和可用性，特別是在醫療保健預算緊張的開發中國家。

新興市場的成長

胜肽療法在新興市場有巨大的成長空間，特別是在亞太地區、拉丁美洲和非洲。這些地區的醫療保健成本不斷增加，慢性病發病率上升，醫療基礎設施不斷進步。改善獲得尖端醫療保健的機會是這些地區政府和醫療保健組織的首要任務。透過正確進入這些市場，公司可以接觸到龐大且不斷擴大的患者群體。此外，與當地醫療保健提供者合作並符合當地監管要求可以順利進入和拓展新市場。

生物製藥與小分子藥物的激烈競爭

胜肽療法的市場競爭對手包括知名的小分子藥物和生技藥品。小分子藥物因其保存期限長、生物有效性和製造成本低而通常受到青睞。基因治療和單株抗體等生物製藥因其高特異性和有效性而被廣泛用於治療多種慢性和複雜疾病。此外，由於這些替代品已確立的市場地位，胜肽療法很難起步。為了在競爭中取得成功，產品必須在有效性、安全性、便利性等方面與競爭對手顯著不同。

COVID-19 的影響：

胜肽治療市場受到COVID-19大流行的多種影響，既阻礙又加速了該行業的成長。由於供應鏈中斷和對抗疫情的醫療保健資金的重新分配，研究和生產能力暫時受到阻礙。然而，對高效藥物和疫苗的迫切需求使人們對基於勝胜肽的治療方法的潛力產生了關注，從而導致相關產品的資金增加並加速了監管核准。此外，疫情也引起了人們對創新藥物輸送方法和強大供應鏈重要性的關注，引發了最終可能服務於市場的發展和調整。

預計創新領域將在預測期內成為最大的領域

胜肽治療市場由創新領域主導。這一優勢是由創新勝胜肽藥物研發的進步所推動的，這些藥物為多種疾病提供標靶治療方法，包括糖尿病、心血管疾病和癌症。新型勝胜肽通常被設計為具有高選擇性、有效性和安全性，填補醫學領域的空白並提供比現有治療方法更好的治療選擇。此外，該市場的成長是由大量的研發支出以及對創新治療的監管支持所推動的。

預計口腔細分市場在預測期間內年複合成長率最高

在勝胜肽治療市場中，口服製劑領域預計將以最高的年複合成長率成長。迄今為止，胜肽藥物由於生物有效性低且易在消化器官系統中被酶分解而難以口服給藥。然而，藥物傳遞技術的新發展，例如防止勝胜肽分解和改善吸收的口服製劑的開發，正在改變這種狀況。此外，腸溶衣、酵素抑制劑和奈米顆粒載體等創新使口服勝胜肽療法更具吸引力和可行性。

比例最高的地區：

胜肽治療市場由北美主導。這項優勢由多種因素支撐，包括強大的研發基礎、慢性病的高盛行率以及有利的法律規範。該地區重要的製藥和生物技術公司以及注重創新和技術進步的公司為該地區的主導地位做出了貢獻。此外，患者和醫療保健提供者對胜肽療法益處的認知不斷提高，對個人化治療和精準醫療的投資不斷增加，正在推動北美市場的成長。

年複合成長率最高的地區：

胜肽治療市場預計將見證亞太地區最高的年複合成長率。生物製藥行業的成長、慢性病的流行、醫療保健成本的上升以及研發支出的增加推動了成長。中國、印度、日本和韓國正在成為全球製藥業的主要參與者，並專注於開發勝胜肽藥物等新型治療方法。此外，由於積極的政府措施、改善的醫療基礎設施和龐大的患者數量，亞太地區具有巨大的市場擴張潛力。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

根據 Stratistics MRC 的數據，2024 年全球勝胜肽治療市場規模為 491.5 億美元，預計預測期內年複合成長率為 7.63%，到 2030 年將達到 764.1 億美元。胜肽療法是一類令人興奮的新型藥物，它利用胜肽（短鏈氨基酸）來靶向和改變特定的生理途徑。它們具有卓越的選擇性和作用於多種生物標的（包括荷爾蒙、酵素和受體）的能力，使得這些治療方法特別有用。當將新治療方法與舊的小分子藥物進行比較時，這種精確度可以開發出副作用較少的治療方法。此外，利用創新方法治療糖尿病、癌症和細菌感染等疾病，胜肽療法已應用於腫瘤學、內分泌學和感染疾病等醫學專業。

據美國糖尿病協會稱，胜肽療法是糖尿病治療的重要進步，與傳統治療方法相比，它可以改善血糖控制並減少副作用。

慢性病增加

糖尿病、癌症、心臟病和神經系統疾病等慢性疾病在全球日益流行，推動了對更複雜治療方法的需求。胜肽療法由於能夠精確靶向患病細胞和途徑，因此為傳統療法提供了一個有前景的替代方案。例如，GLP-1受體促效劑是胜肽藥物，對糖尿病患者的血糖控制具有優異的效果。此外，胜肽治療市場受到慢性病患者數量不斷增加的推動，導致對更安全、更有效的治療的需求增加。

製造成本增加

勝胜肽治療藥物是使用昂貴且複雜的合成技術製造的，例如重組 DNA 技術和固相勝胜肽合成 (SPPS)。這些程序需要昂貴的機械、高度純化的試劑和嚴格的品管程序，以確保所需產品的純度和效力。此外，從實驗室生產擴大到商業規模可能會令人望而卻步。由於製造成本高昂，這些產品最終價格昂貴，這可能會限制可負擔性和可用性，特別是在醫療保健預算緊張的開發中國家。

新興市場的成長

胜肽療法在新興市場有巨大的成長空間，特別是在亞太地區、拉丁美洲和非洲。這些地區的醫療保健成本不斷增加，慢性病發病率上升，醫療基礎設施不斷進步。改善獲得尖端醫療保健的機會是這些地區政府和醫療保健組織的首要任務。透過正確進入這些市場，公司可以接觸到龐大且不斷擴大的患者群體。此外，與當地醫療保健提供者合作並符合當地監管要求可以順利進入和拓展新市場。

生物製藥與小分子藥物的激烈競爭

胜肽療法的市場競爭對手包括知名的小分子藥物和生技藥品。小分子藥物因其保存期限長、生物有效性和製造成本低而通常受到青睞。基因治療和單株抗體等生物製藥因其高特異性和有效性而被廣泛用於治療多種慢性和複雜疾病。此外，由於這些替代品已確立的市場地位，胜肽療法很難起步。為了在競爭中取得成功，產品必須在有效性、安全性、便利性等方面與競爭對手顯著不同。

COVID-19 的影響：

胜肽治療市場受到COVID-19大流行的多種影響，既阻礙又加速了該行業的成長。由於供應鏈中斷和對抗疫情的醫療保健資金重新分配，研究和生產能力暫時受到阻礙。然而，對高效藥物和疫苗的迫切需求使人們對基於勝胜肽的治療方法的潛力產生了關注，從而導致相關產品的資金增加並加速了監管核准。此外，疫情也引起了人們對創新藥物輸送方法和強大供應鏈重要性的關注，引發了最終可能服務於市場的發展和調整。

預計創新領域將在預測期內成為最大的領域

胜肽治療市場由創新領域主導。這一優勢是由創新勝胜肽藥物研發的進步所推動的，這些藥物為多種疾病提供標靶治療方法，包括糖尿病、心血管疾病和癌症。新型勝胜肽通常被設計為具有高選擇性、有效性和安全性，填補醫學領域的空白並提供比現有治療方法更好的治療選擇。此外，該市場的成長是由大量的研發支出以及對創新治療的監管支持所推動的。

預計口腔細分市場在預測期間內年複合成長率最高

在勝胜肽治療市場中，口服製劑領域預計將以最高的年複合成長率成長。迄今為止，胜肽藥物由於其生物有效性低且易於在消化器官系統中被酶分解而難以口服給藥。然而，藥物傳遞技術的新發展，例如防止勝胜肽分解和改善吸收的口服製劑的開發，正在改變這種狀況。此外，腸溶衣、酵素抑制劑和奈米顆粒載體等創新使口服勝胜肽療法更具吸引力和可行性。

比例最高的地區：

胜肽治療市場由北美主導。這項優勢由多種因素促成，包括強大的研發基礎、慢性病的高盛行率以及有利的法律規範。該地區重要的製藥和生物技術公司以及注重創新和技術進步的公司為該地區的主導地位做出了貢獻。此外，患者和醫療保健提供者對胜肽療法益處的認知不斷提高，對個人化治療和精準醫療的投資不斷增加，正在推動北美市場的成長。

年複合成長率最高的地區：

胜肽治療市場預計將見證亞太地區最高的年複合成長率。生物製藥行業的成長、慢性病的流行、醫療保健成本的上升以及研發支出的增加推動了成長。中國、印度、日本和韓國正在成為全球製藥業的主要參與者，並專注於開發勝胜肽藥物等新型治療方法。此外，由於積極的政府措施、改善的醫療基礎設施和龐大的患者數量，亞太地區具有巨大的市場擴張潛力。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球勝胜肽治療市場：依類型

  • 品牌
  • 非專利的
  • 創新的
  • 其他類型

第6章全球勝胜肽治療藥物市場：依給藥途徑

  • 胃腸外的
  • 口服
  • 黏膜
  • 注射
  • 鼻腔
  • 其他給藥途徑

第7章全球勝胜肽治療市場：依製造商類型

  • 公司內部
  • CMO
  • 其他製造商類型

第8章全球勝胜肽治療市場：依分子類型

  • 加壓素
  • 生長抑制素
  • 利鈉劑
  • 黃體激素(LH) 釋放激素 (LHRH)
  • 胰島素
  • 免疫勝胜肽
  • 升糖素及其類似物
  • 抑鈣素
  • 其他分子類型

第9章全球勝胜肽治療市場：依技術分類

  • 固相勝胜肽合成（SPPS）
  • 液相胜肽合成（LPPS）
  • 混合技術
  • 其他技術

第10章全球勝胜肽治療市場：依應用分類

  • 代謝紊亂
  • 癌症
  • 心血管疾病
  • 胃腸道疾病
  • 中樞神經系統疾病
  • 感染疾病
  • 呼吸系統疾病
  • 疼痛管理
  • 租賃障礙
  • 皮膚科
  • 其他用途

第11章全球勝胜肽治療市場：依最終用戶分類

  • 製藥和生物技術產業
  • 醫院
  • 受託研究機構
  • 學術研究所
  • 其他最終用戶

第12章全球勝胜肽治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第13章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第14章 公司概況

  • Eli Lilly & Company
  • AstraZeneca PLC
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Bausch Health Companies Inc
  • Ever Neuro Pharma GmbH
  • AbbVie, Inc.
  • Ironwood Pharmaceuticals Inc.
  • Sanofi SA
  • Novo Nordisk A/S
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • GlaxoSmithKline plc
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: SMRC26372

According to Stratistics MRC, the Global Peptide Therapeutics Market is accounted for $49.15 billion in 2024 and is expected to reach $76.41 billion by 2030 growing at a CAGR of 7.63% during the forecast period. Peptide therapeutics are a new and exciting class of pharmaceuticals that target and modify particular physiological pathways by using peptides, which are short chains of amino acids. With their exceptional selectivity and capacity to engage with a wide variety of biological targets, such as hormones, enzymes, and receptors, these treatments are particularly useful. Comparing new treatments to older small-molecule medications, this precision allows for the development of therapies with fewer side effects. Moreover, utilizing innovative methods to treat ailments like diabetes, cancer, and bacterial infections, peptide therapeutics are used in oncology, endocrinology, and infectious diseases, among other medical specialties.

According to the American Diabetes Association, peptide therapeutics represent a significant advancement in the treatment of diabetes, offering improved glucose control and reduced side effects compared to conventional therapies.

Market Dynamics:

Driver:

Growing rate of chronic illnesses

The increasing prevalence of chronic illnesses worldwide, including diabetes, cancer, heart disease, and neurological disorders, is driving up demand for more sophisticated treatment alternatives. Peptide therapeutics presents a promising substitute for conventional therapies because of their capacity to precisely target diseased cells and pathways. GLP-1 receptor agonists, for example, are peptide medications that have demonstrated superior efficacy in glycemic control in diabetes. Furthermore, the market for peptide therapeutics is being driven by the increasing number of patients with chronic conditions, which is driving the demand for safer and more effective treatments.

Restraint:

Elevated production expenses

Peptide therapeutics is made using costly and intricate synthesis techniques like recombinant DNA technology and solid-phase peptide synthesis (SPPS). To guarantee the desired product's purity and effectiveness, these procedures call for expensive machinery, high-purity reagents, and stringent quality control procedures. Additionally, it can be unaffordable to scale up production from a laboratory to a commercial scale. Because of their high production costs, these products end up being more expensive, which can restrict their affordability and accessibility, particularly in developing nations where healthcare budgets are tight.

Opportunity:

Growth in emerging markets

Peptide therapeutics has a lot of room to grow in emerging markets, especially in Asia-Pacific, Latin America, and Africa. These areas are seeing increases in the cost of healthcare, a rise in the incidence of chronic illnesses, and advancements in the infrastructure of healthcare. Improving access to cutting-edge medical treatments is the main priority for these regions' governments and healthcare institutions. Companies can access a sizable and expanding patient population by judiciously entering these markets. Furthermore, smoother entry and expansion into new markets can be facilitated by working with regional healthcare providers and adjusting to local regulatory requirements.

Threat:

Fierce rivalry between biologics and small molecules

Market competitors for peptide therapeutics include well-known small-molecule medications and biologics. Because of their longer shelf life, oral bioavailability, and lower production costs, small-molecule drugs are typically preferred. Biologics are widely used in the treatment of a wide range of chronic and complex diseases because they have high specificity and efficacy, such as gene therapies and monoclonal antibodies. Moreover, peptide therapies have a difficult time taking off due to the established market positions of these alternatives; in order to successfully compete, they must significantly differ from the competition in terms of efficacy, safety, or convenience.

Covid-19 Impact:

The peptide therapeutics market was affected by the COVID-19 pandemic in a variety of ways, which both hampered and accelerated the industry's growth. Research and production capacities were momentarily hampered by supply chain disruptions and the reallocation of healthcare funds to pandemic management. But the pressing need for efficient medications and vaccines brought peptide-based therapies' potential to light, resulting in more funding and quicker regulatory approvals for related goods. Additionally, the pandemic also brought attention to the significance of creative drug delivery methods and robust supply chains, which sparked developments and adjustments that might eventually help the market.

The Innovative segment is expected to be the largest during the forecast period

The market for peptide therapeutics is dominated by the innovative segment. This dominance is fueled by the ongoing research and development of innovative peptide medications, which provide focused therapies for a variety of illnesses, such as diabetes, cardiovascular disease, and cancer. Novel peptides are generally engineered to possess heightened selectivity, effectiveness, and safety characteristics, filling gaps in the medical field and providing better therapeutic alternatives than established therapies. Furthermore, growth in this market has been driven by significant R&D expenditures as well as regulatory support for innovative treatments.

The Oral segment is expected to have the highest CAGR during the forecast period

In the peptide therapeutics market, the oral segment is anticipated to grow at the highest CAGR. Peptide medications have historically had difficulty being administered orally because of their low bioavailability and vulnerability to enzymatic breakdown in the gastrointestinal system. But new developments in drug delivery technologies are changing this, like the creation of oral formulations that prevent peptides from degrading and improve their absorption. Moreover, enteric coatings, enzyme inhibitors, and nanoparticle carriers are some of the innovations that are making oral peptide therapeutics more appealing and feasible.

Region with largest share:

The market for peptide therapeutics is dominated by North America. Numerous factors, such as a strong research and development base, a high incidence of chronic illnesses, and advantageous regulatory frameworks, are responsible for this dominance. Contributing to the region's leading position are important pharmaceutical and biotechnology companies, as well as a strong emphasis on innovation and technological advancements. Additionally, growing patient and healthcare professional awareness of the advantages of peptide therapeutics, along with rising investments in personalized therapies and precision medicine, are driving market growth in North America.

Region with highest CAGR:

The peptide therapeutics market is expected to grow at the highest CAGR in the Asia-Pacific area. The biopharmaceutical industry is growing, chronic disease prevalence is rising, healthcare costs are rising, and R&D spending is rising, among other factors driving this growth. China, India, Japan, and South Korea are becoming major players in the global pharmaceutical industry, focusing on the development of novel treatments such as peptide drugs. Furthermore, the Asia-Pacific region offers substantial prospects for market expansion due to favourable government initiatives, improving healthcare infrastructure, and a sizable patient population.

Key players in the market

Some of the key players in Peptide Therapeutics market include Eli Lilly & Company, AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Bausch Health Companies Inc, Ever Neuro Pharma GmbH, AbbVie, Inc., Ironwood Pharmaceuticals Inc., Sanofi SA, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Amgen Inc., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd. And Teva Pharmaceutical Industries Ltd.

Key Developments:

In May 2024, AstraZeneca has entered a worldwide licence and option agreement with Nona Biosciences for a preclinical monoclonal antibody. The deal focuses on the development of the antibody to develop targeted tumour therapies.

In January 2024, Roche and MOMA Therapeutics have signed a strategic partnership and licencing agreement for discovering drug targets for cancer. Under the alliance, Roche will obtain access to MOMA's KnowledgeBase platform to identify and prosecute new drug targets that are involved in the growth and survival of cancer cells.

In October 2023, French biotech company Mablink has entered an agreement to be acquired by Eli Lilly. The deal is subject to approval from the French Ministry of the Economy. Lilly plans to utilise Mablink's PSARLink technology, which disguises cancer-killing molecules, allowing them to be delivered precisely to cancer cells while sparing healthy cells. The technology will broaden the use of antibody-drug conjugates (ADCs).

Types Covered:

  • Branded
  • Generic
  • Innovative
  • Other Types

Route of Administrations Covered:

  • Parenteral
  • Oral
  • Mucosal
  • Injection
  • Nasal
  • Other Routes of Administrations

Manufacturer Types Covered:

  • In-house
  • CMO
  • Other Manufacturer Types

Molecule Types Covered:

  • Vasopressin
  • Somatostatin
  • Natriuretic
  • Luteinizing Hormone (LH)-Releasing Hormone (LHRH)
  • Insulins
  • Immunopeptide
  • Glucagon and Analogs
  • Calcitonin
  • Other Molecule Types

Technologies Covered:

  • Solid Phase Peptide Synthesis (SPPS)
  • Liquid Phase Peptide Synthesis (LPPS)
  • Hybrid Technology
  • Other Technologies

Applications Covered:

  • Metabolic Disorders
  • Cancer
  • Cardiovascular Disorders
  • Gastrointestinal Disorders
  • Central Nervous System Disorders
  • Infectious Diseases
  • Respiratory Disorders
  • Pain Management
  • Rental Disorders
  • Dermatology
  • Other Applications

End Users Covered:

  • Pharmaceutical and Biotechnology Industries
  • Hospitals
  • Contract Research Organization
  • Academic and Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

According to Stratistics MRC, the Global Peptide Therapeutics Market is accounted for $49.15 billion in 2024 and is expected to reach $76.41 billion by 2030 growing at a CAGR of 7.63% during the forecast period. Peptide therapeutics are a new and exciting class of pharmaceuticals that target and modify particular physiological pathways by using peptides, which are short chains of amino acids. With their exceptional selectivity and capacity to engage with a wide variety of biological targets, such as hormones, enzymes, and receptors, these treatments are particularly useful. Comparing new treatments to older small-molecule medications, this precision allows for the development of therapies with fewer side effects. Moreover, utilizing innovative methods to treat ailments like diabetes, cancer, and bacterial infections, peptide therapeutics are used in oncology, endocrinology, and infectious diseases, among other medical specialties.

According to the American Diabetes Association, peptide therapeutics represent a significant advancement in the treatment of diabetes, offering improved glucose control and reduced side effects compared to conventional therapies.

Market Dynamics:

Driver:

Growing rate of chronic illnesses

The increasing prevalence of chronic illnesses worldwide, including diabetes, cancer, heart disease, and neurological disorders, is driving up demand for more sophisticated treatment alternatives. Peptide therapeutics presents a promising substitute for conventional therapies because of their capacity to precisely target diseased cells and pathways. GLP-1 receptor agonists, for example, are peptide medications that have demonstrated superior efficacy in glycemic control in diabetes. Furthermore, the market for peptide therapeutics is being driven by the increasing number of patients with chronic conditions, which is driving the demand for safer and more effective treatments.

Restraint:

Elevated production expenses

Peptide therapeutics is made using costly and intricate synthesis techniques like recombinant DNA technology and solid-phase peptide synthesis (SPPS). To guarantee the desired product's purity and effectiveness, these procedures call for expensive machinery, high-purity reagents, and stringent quality control procedures. Additionally, it can be unaffordable to scale up production from a laboratory to a commercial scale. Because of their high production costs, these products end up being more expensive, which can restrict their affordability and accessibility, particularly in developing nations where healthcare budgets are tight.

Opportunity:

Growth in emerging markets

Peptide therapeutics has a lot of room to grow in emerging markets, especially in Asia-Pacific, Latin America, and Africa. These areas are seeing increases in the cost of healthcare, a rise in the incidence of chronic illnesses, and advancements in the infrastructure of healthcare. Improving access to cutting-edge medical treatments is the main priority for these regions' governments and healthcare institutions. Companies can access a sizable and expanding patient population by judiciously entering these markets. Furthermore, smoother entry and expansion into new markets can be facilitated by working with regional healthcare providers and adjusting to local regulatory requirements.

Threat:

Fierce rivalry between biologics and small molecules

Market competitors for peptide therapeutics include well-known small-molecule medications and biologics. Because of their longer shelf life, oral bioavailability, and lower production costs, small-molecule drugs are typically preferred. Biologics are widely used in the treatment of a wide range of chronic and complex diseases because they have high specificity and efficacy, such as gene therapies and monoclonal antibodies. Moreover, peptide therapies have a difficult time taking off due to the established market positions of these alternatives; in order to successfully compete, they must significantly differ from the competition in terms of efficacy, safety, or convenience.

Covid-19 Impact:

The peptide therapeutics market was affected by the COVID-19 pandemic in a variety of ways, which both hampered and accelerated the industry's growth. Research and production capacities were momentarily hampered by supply chain disruptions and the reallocation of healthcare funds to pandemic management. But the pressing need for efficient medications and vaccines brought peptide-based therapies' potential to light, resulting in more funding and quicker regulatory approvals for related goods. Additionally, the pandemic also brought attention to the significance of creative drug delivery methods and robust supply chains, which sparked developments and adjustments that might eventually help the market.

The Innovative segment is expected to be the largest during the forecast period

The market for peptide therapeutics is dominated by the innovative segment. This dominance is fueled by the ongoing research and development of innovative peptide medications, which provide focused therapies for a variety of illnesses, such as diabetes, cardiovascular disease, and cancer. Novel peptides are generally engineered to possess heightened selectivity, effectiveness, and safety characteristics, filling gaps in the medical field and providing better therapeutic alternatives than established therapies. Furthermore, growth in this market has been driven by significant R&D expenditures as well as regulatory support for innovative treatments.

The Oral segment is expected to have the highest CAGR during the forecast period

In the peptide therapeutics market, the oral segment is anticipated to grow at the highest CAGR. Peptide medications have historically had difficulty being administered orally because of their low bioavailability and vulnerability to enzymatic breakdown in the gastrointestinal system. But new developments in drug delivery technologies are changing this, like the creation of oral formulations that prevent peptides from degrading and improve their absorption. Moreover, enteric coatings, enzyme inhibitors, and nanoparticle carriers are some of the innovations that are making oral peptide therapeutics more appealing and feasible.

Region with largest share:

The market for peptide therapeutics is dominated by North America. Numerous factors, such as a strong research and development base, a high incidence of chronic illnesses, and advantageous regulatory frameworks, are responsible for this dominance. Contributing to the region's leading position are important pharmaceutical and biotechnology companies, as well as a strong emphasis on innovation and technological advancements. Additionally, growing patient and healthcare professional awareness of the advantages of peptide therapeutics, along with rising investments in personalized therapies and precision medicine, are driving market growth in North America.

Region with highest CAGR:

The peptide therapeutics market is expected to grow at the highest CAGR in the Asia-Pacific area. The biopharmaceutical industry is growing, chronic disease prevalence is rising, healthcare costs are rising, and R&D spending is rising, among other factors driving this growth. China, India, Japan, and South Korea are becoming major players in the global pharmaceutical industry, focusing on the development of novel treatments such as peptide drugs. Furthermore, the Asia-Pacific region offers substantial prospects for market expansion due to favourable government initiatives, improving healthcare infrastructure, and a sizable patient population.

Key players in the market

Some of the key players in Peptide Therapeutics market include Eli Lilly & Company, AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Bausch Health Companies Inc, Ever Neuro Pharma GmbH, AbbVie, Inc., Ironwood Pharmaceuticals Inc., Sanofi SA, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Amgen Inc., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd. And Teva Pharmaceutical Industries Ltd.

Key Developments:

In May 2024, AstraZeneca has entered a worldwide licence and option agreement with Nona Biosciences for a preclinical monoclonal antibody. The deal focuses on the development of the antibody to develop targeted tumour therapies.

In January 2024, Roche and MOMA Therapeutics have signed a strategic partnership and licencing agreement for discovering drug targets for cancer. Under the alliance, Roche will obtain access to MOMA's KnowledgeBase platform to identify and prosecute new drug targets that are involved in the growth and survival of cancer cells.

In October 2023, French biotech company Mablink has entered an agreement to be acquired by Eli Lilly. The deal is subject to approval from the French Ministry of the Economy. Lilly plans to utilise Mablink's PSARLink technology, which disguises cancer-killing molecules, allowing them to be delivered precisely to cancer cells while sparing healthy cells. The technology will broaden the use of antibody-drug conjugates (ADCs).

Types Covered:

  • Branded
  • Generic
  • Innovative
  • Other Types

Route of Administrations Covered:

  • Parenteral
  • Oral
  • Mucosal
  • Injection
  • Nasal
  • Other Routes of Administrations

Manufacturer Types Covered:

  • In-house
  • CMO
  • Other Manufacturer Types

Molecule Types Covered:

  • Vasopressin
  • Somatostatin
  • Natriuretic
  • Luteinizing Hormone (LH)-Releasing Hormone (LHRH)
  • Insulins
  • Immunopeptide
  • Glucagon and Analogs
  • Calcitonin
  • Other Molecule Types

Technologies Covered:

  • Solid Phase Peptide Synthesis (SPPS)
  • Liquid Phase Peptide Synthesis (LPPS)
  • Hybrid Technology
  • Other Technologies

Applications Covered:

  • Metabolic Disorders
  • Cancer
  • Cardiovascular Disorders
  • Gastrointestinal Disorders
  • Central Nervous System Disorders
  • Infectious Diseases
  • Respiratory Disorders
  • Pain Management
  • Rental Disorders
  • Dermatology
  • Other Applications

End Users Covered:

  • Pharmaceutical and Biotechnology Industries
  • Hospitals
  • Contract Research Organization
  • Academic and Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Peptide Therapeutics Market, By Type

  • 5.1 Introduction
  • 5.2 Branded
  • 5.3 Generic
  • 5.4 Innovative
  • 5.5 Other Types

6 Global Peptide Therapeutics Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Parenteral
  • 6.3 Oral
  • 6.4 Mucosal
  • 6.5 Injection
  • 6.6 Nasal
  • 6.7 Other Routes of Administrations

7 Global Peptide Therapeutics Market, By Manufacturer Type

  • 7.1 Introduction
  • 7.2 In-house
  • 7.3 CMO
  • 7.4 Other Manufacturer Types

8 Global Peptide Therapeutics Market, By Molecule Type

  • 8.1 Introduction
  • 8.2 Vasopressin
  • 8.3 Somatostatin
  • 8.4 Natriuretic
  • 8.5 Luteinizing Hormone (LH)-Releasing Hormone (LHRH)
  • 8.6 Insulins
  • 8.7 Immunopeptide
  • 8.8 Glucagon and Analogs
  • 8.9 Calcitonin
  • 8.10 Other Molecule Types

9 Global Peptide Therapeutics Market, By Technology

  • 9.1 Introduction
  • 9.2 Solid Phase Peptide Synthesis (SPPS)
  • 9.3 Liquid Phase Peptide Synthesis (LPPS)
  • 9.4 Hybrid Technology
  • 9.5 Other Technologies

10 Global Peptide Therapeutics Market, By Application

  • 10.1 Introduction
  • 10.2 Metabolic Disorders
  • 10.3 Cancer
  • 10.4 Cardiovascular Disorders
  • 10.5 Gastrointestinal Disorders
  • 10.6 Central Nervous System Disorders
  • 10.7 Infectious Diseases
  • 10.8 Respiratory Disorders
  • 10.9 Pain Management
  • 10.10 Rental Disorders
  • 10.11 Dermatology
  • 10.12 Other Applications

11 Global Peptide Therapeutics Market, By End User

  • 11.1 Introduction
  • 11.2 Pharmaceutical and Biotechnology Industries
  • 11.3 Hospitals
  • 11.4 Contract Research Organization
  • 11.5 Academic and Research Institutes
  • 11.6 Other End Users

12 Global Peptide Therapeutics Market, By Geography

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 US
    • 12.2.2 Canada
    • 12.2.3 Mexico
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 Italy
    • 12.3.4 France
    • 12.3.5 Spain
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 Japan
    • 12.4.2 China
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 New Zealand
    • 12.4.6 South Korea
    • 12.4.7 Rest of Asia Pacific
  • 12.5 South America
    • 12.5.1 Argentina
    • 12.5.2 Brazil
    • 12.5.3 Chile
    • 12.5.4 Rest of South America
  • 12.6 Middle East & Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 UAE
    • 12.6.3 Qatar
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 Key Developments

  • 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 13.2 Acquisitions & Mergers
  • 13.3 New Product Launch
  • 13.4 Expansions
  • 13.5 Other Key Strategies

14 Company Profiling

  • 14.1 Eli Lilly & Company
  • 14.2 AstraZeneca PLC
  • 14.3 F. Hoffmann-La Roche Ltd.
  • 14.4 Novartis AG
  • 14.5 Pfizer Inc.
  • 14.6 Bausch Health Companies Inc
  • 14.7 Ever Neuro Pharma GmbH
  • 14.8 AbbVie, Inc.
  • 14.9 Ironwood Pharmaceuticals Inc.
  • 14.10 Sanofi SA
  • 14.11 Novo Nordisk A/S
  • 14.12 Takeda Pharmaceutical Company Limited
  • 14.13 Amgen Inc.
  • 14.14 GlaxoSmithKline plc
  • 14.15 Sun Pharmaceutical Industries Ltd.
  • 14.16 Teva Pharmaceutical Industries Ltd.

List of Tables

  • Table 1 Global Peptide Therapeutics Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Peptide Therapeutics Market Outlook, By Type (2022-2030) ($MN)
  • Table 3 Global Peptide Therapeutics Market Outlook, By Branded (2022-2030) ($MN)
  • Table 4 Global Peptide Therapeutics Market Outlook, By Generic (2022-2030) ($MN)
  • Table 5 Global Peptide Therapeutics Market Outlook, By Innovative (2022-2030) ($MN)
  • Table 6 Global Peptide Therapeutics Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 7 Global Peptide Therapeutics Market Outlook, By Route of Administration (2022-2030) ($MN)
  • Table 8 Global Peptide Therapeutics Market Outlook, By Parenteral (2022-2030) ($MN)
  • Table 9 Global Peptide Therapeutics Market Outlook, By Oral (2022-2030) ($MN)
  • Table 10 Global Peptide Therapeutics Market Outlook, By Mucosal (2022-2030) ($MN)
  • Table 11 Global Peptide Therapeutics Market Outlook, By Injection (2022-2030) ($MN)
  • Table 12 Global Peptide Therapeutics Market Outlook, By Nasal (2022-2030) ($MN)
  • Table 13 Global Peptide Therapeutics Market Outlook, By Other Routes of Administrations (2022-2030) ($MN)
  • Table 14 Global Peptide Therapeutics Market Outlook, By Manufacturer Type (2022-2030) ($MN)
  • Table 15 Global Peptide Therapeutics Market Outlook, By In-house (2022-2030) ($MN)
  • Table 16 Global Peptide Therapeutics Market Outlook, By CMO (2022-2030) ($MN)
  • Table 17 Global Peptide Therapeutics Market Outlook, By Other Manufacturer Types (2022-2030) ($MN)
  • Table 18 Global Peptide Therapeutics Market Outlook, By Molecule Type (2022-2030) ($MN)
  • Table 19 Global Peptide Therapeutics Market Outlook, By Vasopressin (2022-2030) ($MN)
  • Table 20 Global Peptide Therapeutics Market Outlook, By Somatostatin (2022-2030) ($MN)
  • Table 21 Global Peptide Therapeutics Market Outlook, By Natriuretic (2022-2030) ($MN)
  • Table 22 Global Peptide Therapeutics Market Outlook, By Luteinizing Hormone (LH)-Releasing Hormone (LHRH) (2022-2030) ($MN)
  • Table 23 Global Peptide Therapeutics Market Outlook, By Insulins (2022-2030) ($MN)
  • Table 24 Global Peptide Therapeutics Market Outlook, By Immunopeptide (2022-2030) ($MN)
  • Table 25 Global Peptide Therapeutics Market Outlook, By Glucagon and Analogs (2022-2030) ($MN)
  • Table 26 Global Peptide Therapeutics Market Outlook, By Calcitonin (2022-2030) ($MN)
  • Table 27 Global Peptide Therapeutics Market Outlook, By Other Molecule Types (2022-2030) ($MN)
  • Table 28 Global Peptide Therapeutics Market Outlook, By Technology (2022-2030) ($MN)
  • Table 29 Global Peptide Therapeutics Market Outlook, By Solid Phase Peptide Synthesis (SPPS) (2022-2030) ($MN)
  • Table 30 Global Peptide Therapeutics Market Outlook, By Liquid Phase Peptide Synthesis (LPPS) (2022-2030) ($MN)
  • Table 31 Global Peptide Therapeutics Market Outlook, By Hybrid Technology (2022-2030) ($MN)
  • Table 32 Global Peptide Therapeutics Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 33 Global Peptide Therapeutics Market Outlook, By Application (2022-2030) ($MN)
  • Table 34 Global Peptide Therapeutics Market Outlook, By Metabolic Disorders (2022-2030) ($MN)
  • Table 35 Global Peptide Therapeutics Market Outlook, By Cancer (2022-2030) ($MN)
  • Table 36 Global Peptide Therapeutics Market Outlook, By Cardiovascular Disorders (2022-2030) ($MN)
  • Table 37 Global Peptide Therapeutics Market Outlook, By Gastrointestinal Disorders (2022-2030) ($MN)
  • Table 38 Global Peptide Therapeutics Market Outlook, By Central Nervous System Disorders (2022-2030) ($MN)
  • Table 39 Global Peptide Therapeutics Market Outlook, By Infectious Diseases (2022-2030) ($MN)
  • Table 40 Global Peptide Therapeutics Market Outlook, By Respiratory Disorders (2022-2030) ($MN)
  • Table 41 Global Peptide Therapeutics Market Outlook, By Pain Management (2022-2030) ($MN)
  • Table 42 Global Peptide Therapeutics Market Outlook, By Rental Disorders (2022-2030) ($MN)
  • Table 43 Global Peptide Therapeutics Market Outlook, By Dermatology (2022-2030) ($MN)
  • Table 44 Global Peptide Therapeutics Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 45 Global Peptide Therapeutics Market Outlook, By End User (2022-2030) ($MN)
  • Table 46 Global Peptide Therapeutics Market Outlook, By Pharmaceutical and Biotechnology Industries (2022-2030) ($MN)
  • Table 47 Global Peptide Therapeutics Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 48 Global Peptide Therapeutics Market Outlook, By Contract Research Organization (2022-2030) ($MN)
  • Table 49 Global Peptide Therapeutics Market Outlook, By Academic and Research Institutes (2022-2030) ($MN)
  • Table 50 Global Peptide Therapeutics Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.